Insights
Professional
Practice
Industry
Region
Trending Topics
Location
Type
Sort by:
Client Alerts 4 results
Client Alert | 3 min read | 08.02.23
Amgen v. Sanofi: Implications for ANDA and aBLA Parties
Pharmaceutical innovators typically seek broad patent protection for their discoveries in order to prevent others from exploiting not only the specific embodiments the innovator wishes to pursue commercially, but also functional equivalents. But what happens when the additional functional equivalents that the innovator seeks to protect are not expressly disclosed in the patent? The Supreme Court recently addressed this issue in Amgen v. Sanofi.
Client Alert | less than 1 min read | 03.23.21
American Axle: Is it Finally Time for The Supreme Court to Revisit § 101?
Client Alert | less than 1 min read | 04.14.20
Claim Construction Under the BRI Standard: Can An "Incorrect" Interpretation Still Be "Reasonable"?